Fusion Pharmaceuticals to be acquired by AstraZeneca
Canadian Manufacturing
MARCH 19, 2024
HAMILTON and BOSTON — Fusion Pharmaceuticals Inc., Fusion Pharmaceuticals says that RCs have emerged as a promising modality in cancer treatment over recent years. The acquisition brings manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens their presence in Canada.
Let's personalize your content